These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 35928819)

  • 1. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 6. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
    Cassanello G; Luna de Abia A; Falchi L
    Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bispecific antibodies in indolent B-cell lymphomas.
    Radhakrishnan VS; Davies AJ
    Front Immunol; 2023; 14():1295599. PubMed ID: 38274793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting.
    Liu X; Zhao J; Guo X; Song Y
    J Hematol Oncol; 2023 Aug; 16(1):90. PubMed ID: 37537626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?].
    Bücklein V; von Tresckow B; Subklewe M
    Dtsch Med Wochenschr; 2024 May; 149(11):630-637. PubMed ID: 38749439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous epcoritamab monotherapy in Japanese adults with relapsed/refractory diffuse large B-cell lymphoma.
    Izutsu K; Kumode T; Yuda J; Nagai H; Mishima Y; Suehiro Y; Yamamoto K; Fujisaki T; Ishitsuka K; Ishizawa K; Ikezoe T; Nishikori M; Akahane D; Fujita J; Dinh M; Soong D; Noguchi H; Buchbjerg JK; Favaro E; Fukuhara N
    Cancer Sci; 2023 Dec; 114(12):4643-4653. PubMed ID: 37921363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
    Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
    Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma.
    Zinzani PL; Minotti G
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):177-190. PubMed ID: 34741682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Novel Therapeutic Landscape for Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Nuvvula S; Dahiya S; Patel SA
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):362-372. PubMed ID: 34922844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies for the treatment of lymphomas: Promises and challenges.
    Schuster SJ
    Hematol Oncol; 2021 Jun; 39 Suppl 1():113-116. PubMed ID: 34105818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
    Salvaris R; Ong J; Gregory GP
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.